Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#2290 PRRT in Hindgut and Cancer of Unknown Primary NEN

Introduction: There are limited data regarding PRRT in hindgut and CUP (cancer of unknown primary).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Ćwikla J

Authors: Kolasińska-Ćwikła A, Lewczuk-Myślińska A, Cichocki A, Roszkowska-Purska K, Dobkowski P,

Keywords: NENs, PRRT, Hindgut, CUP,

#1865 Evolution of Gastroenteropancreatic Neuroendocrine Tumors – Experiene of a Romanian Endocrine Clinic

Introduction: GEP-NETs (gastroenteropancreatic neuroendocrine tumors) are a heterogenous group of tumors.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Poiana C

Authors: Baciu I, Galoiu S, Trifanescu R, Capatina C, Dumitrascu A,

Keywords: GEP-NETs,

#754 Effect of Dacarbazine Chemotherapy in Well-Differentiated Neuroendocrine Tumors

Introduction: Streptozocin-based chemotherapies are widely used in pancreatic NEN. Dacarbazine (DTIC) (650mg/m2 every four weeks) can easily be applied in an outpatient setting, but data on efficacy are limited.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Mueller D, Krug S, Majumder M, Gress T, Rinke A,

Keywords: NEN, DTIC, MGMT,

#738 Interferon Alpha in the Management of Metastatic Neuroendocrine Tumors: A Retrospective Study in 37 Patients

Introduction: Interferon alpha (IFNα) has not been popular due to perceived lack of efficacy and toxicity profile. Current molecular targeted therapies demonstrate only modest anti-tumor effect with not insignificant toxicity.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: MIRVIS E

Authors: Mirvis E, Garcia-Hernandez J, Mandair D, Cheung V, Toumpanakis C,

Keywords: Interferon,

#534 Effect of Dacarbazine Chemotherapy in Well-Differentiated Neuroendocrine Tumors

Introduction: Despite encouraging results of streptozocin combinations in patients with metastatic endocrine pancreatic tumors, this treatment modality consists of a five-day cycle and can cause renal insufficiency. Dacarbazine (DTIC) (650mg/m2 every four weeks) can easily be applied in an outpatient setting, but data on efficacy are limited.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Müller D, Rinke A, Gress T,

Keywords: neuroendocrine tumor, chemotherapy, dacarbazine,